AMRN
AmarinBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
9
U.S. public peers
Grade Position
Above peers
vs peer average
AMRN vs peer average
84/100
AMRN vs. peer average (B vs. D)
Grade spread
B 2 · C 1 · F 6
Graded peers loaded
Coverage
9 graded
100% of tracked
Peer overview
RDY is the first available peer comparator.
Dr. Reddy's documented a U.S. icosapent ethyl launch and subsequent pricing pressure, making it a relevant historical product-level competitor. Its diversified scale prevents a clean company valuation comparison, and the cited filing does not establish its current product sales. [Dr. Reddy's filing](https://www.sec.gov/Archives/edgar/data/1135951/000157587223000951/rdy-20230331.htm)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
AMRN
Amarin
RDY
Dr Reddy's Laboratories
Grade
B
B
Momentum
13
84
Value
67
64
Sentiment
59
49
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs RDY
AMRN / RDY
Grade Position
Above peers
AMRN vs. peer average (B vs. D)
84/100
Momentum
13
RDYValue
67
AMRNSentiment
59
AMRNRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs AMRN
RDY is the first peer returned for this comparison set.